Additional SCY-078 Posters to be Presented at 8 th Trends in Medical Mycology
Pre-clinical data further highlight SCY-078’s broad spectrum of activity and differentiated attributes
JERSEY CITY, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at IDWeek 2017 , October 4-8, 2017, in San Diego, CA. All presentations will focus on the Company's lead candidate, SCY-078, the first representative of a novel intravenous (IV) and oral triterpenoid antifungal family in Phase 2 clinical development for the treatment of several fungal infections, including invasive candidiasis, invasive aspergillosis and vulvovaginal candidiasis infections. SCYNEXIS will also have additional poster presentations at the 8 th Trends in Medical Mycology , October 6-9, 2017 in Belgrade, Serbia.
IDWeek 2017 posters will be available on the SCYNEXIS website following the event. All abstracts are available on the IDWeek Interactive Program Planner .
Title: SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis Date and Time: Friday, October 6 from 12:30-2:00 p.m. PT Location: Poster Hall CD Poster Presentation #: 1511 Session: Preclinical Study with New Antibiotics and Antifungals
Title: Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates Date and Time: Friday, October 6 from 12:30-2:00 p.m. PT Location: Poster Hall CD Poster Presentation #: 1206 Session: Expanded Spectrum – New Antimicrobial Susceptibility Testing
Title: SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration Date and Time: Friday, October 6 from 12:30-2:00 p.m. PT Location: Poster Hall CD Poster Presentation #: 1508 Session: Preclinical Study with New Antibiotics and Antifungals
About SCY-078 SCY-078 is an antifungal agent in clinical development for the treatment of fungal infections caused by Candida and Aspergillus species. SCY-078 is a triterpenoid, semi-synthetic derivative of the natural product enfumafungin—a structurally distinct and novel class of glucan synthase inhibitor. SCY-078 combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having IV and oral formulations. By belonging to a chemical class distinct from other antifungals, SCY-078 has shown in vitro and in vivo activity against multi-drug resistant pathogens, including azole- and echinocandin-resistant strains. The U.S. Food and Drug Administration granted Fast Track, Qualified Infectious Disease Product and Orphan Drug Designations for the formulations of SCY-078 for the indications of invasive candidiasis (including candidemia ) and invasive aspergillosis.
About SCYNEXIS SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com .
Forward Looking Statement Statements contained in this press release maybe, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS' ability to successfully develop SCY-078, including SCYNEXIS' ability to resolve the FDA's concerns to lift the clinical hold on the IV formulation of SCY-078 on a timely basis, if at all, and obtain FDA approval for SCY-078; the expected costs of studies and when they might begin or be concluded; and SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
C ONTACT:
Med i a Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 cduong@macbiocom.com
I n ve s t o r Relations Susan Kim Argot Partners Tel: 212-203-4433 susan@argotpartners.com
